Company intelligence / Profile preview

Allecra Therapeutics

Weil am Rhein, Baden-Württemberg, Germanyallecra.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Lead product candidate cefepime/enmetazobactam has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial. The company is preparing submissions for marketing approval in the U.S. and EU based on these results[3][6][7].

Therapeutic areas: Infectious Diseases
Modalities: Antibioticssmall molecules
Industry: Biotech

Drug pipeline

1 asset

cefepime + enmetazobactam

Commercial

Indications: Complicated urinary tract infections

Partnerships

Shanghai Haini Pharmaceutical (exclusive licensing agreement for Greater China)Orchid Chemicals & Pharmaceuticals LimitedAcino (exclusive licensing and supply agreement for Gulf Cooperation Council countries and South Africa)

Beyond the preview

Go deeper on Allecra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allecra Therapeutics.